Abstract 5104: Serum metabolomic profiles acquired by gas chromatography-mass spectrometry (GC-MS) distinguish patients with pancreatic adenocarcinoma from those with benign pancreatic disease

Abstract

Abstract Introduction: Pancreatic adenocarcinoma is often difficult to accurately distinguish from benign pancreatic lesions such as pancreatitis. Accurate preoperative identification of patients with benign disease may reduce the number of highly invasive and costly pancreatic resections conducted in this group. This study aims to identify differences in the metabolomic profile of serum between patients with pancreatic adenocarcinoma versus benign pancreatic disease. Methods: Fasting serum samples were collected, as part of an institutional biorepository program (IRB#E20846), from patients with pancreatic adenocarcinoma or benign pancreatic disease. Accompanying clinical data were collected prospectively. Gas chromatography-mass spectrometry (GC-MS) spectra were acquired for aqueous metabolites and analyzed using multivariate methods (orthogonal partial least squares-discriminant analysis, OPLS-DA) using SIMCA-P+ (V12.0.1) software. Metabolite identification was conducted using the TargetSearch approach. Results: Of the 136 included patients, 101 had pancreatic adenocarcinoma and 35 had benign pancreatic disease (26 pancreatitis/pseudocyst, 7 serous cystic neoplasm, 2 other). Median patient age was 66 years, 51.4% were male, 22.8% were jaundiced, and 79.4% presented with a common bile duct stricture or pancreatic mass. The metabolomic profile of serum from patients with pancreatic adenocarcinoma was significantly different from that of patients with benign pancreatic disease based on OPLS-DA modelling (p=0.0004). Overall, the profile contained 168 targeted metabolites, of which 14 were significantly different between malignant and benign pancreatic disease on multivariate modeling. Conclusion: The serum metabolomic profiles of pancreatic adenocarcinoma and benign pancreatic disease differ significantly. Further analysis of these differences may yield a novel serum test to distinguish these lesions in clinical practice. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5104. doi:10.1158/1538-7445.AM2011-5104